Patents by Inventor Richard L. Cate
Richard L. Cate has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110129477Abstract: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.Type: ApplicationFiled: November 23, 2010Publication date: June 2, 2011Inventors: Stephen M. STRITTMATTER, Richard L. Cate, Dinah W.Y. Sah
-
Publication number: 20090175850Abstract: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.Type: ApplicationFiled: November 24, 2008Publication date: July 9, 2009Inventors: Stephen M. Strittmatter, Richard L. Cate, Dina W.Y. Sah
-
Patent number: 7456255Abstract: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.Type: GrantFiled: October 6, 2006Date of Patent: November 25, 2008Assignees: Yale University, Biogen Idec MA Inc.Inventors: Stephen Strittmatter, Richard L. Cate, Dinah W. Y. Sah
-
Patent number: 7173118Abstract: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.Type: GrantFiled: December 12, 2003Date of Patent: February 6, 2007Assignees: Biogen Idec MA Inc., Yale UniversityInventors: Stephen M. Strittmatter, Richard L. Cate, Dinah W. Y. Sah
-
Patent number: 6861509Abstract: Nucleotide and amino acid sequences are provided for compounds which promote tissue growth, as well as methods for modulating tissue growth, for imaging tissues and organs, and for treating patients.Type: GrantFiled: January 21, 2000Date of Patent: March 1, 2005Assignee: Biogen, Inc.Inventors: Michele Sanicola-Nadel, Catherine Hession, Richard L. Cate, Dane S. Worley
-
Patent number: 6677135Abstract: Nucleotide and amino acid sequences are provided for compounds which promote tissue growth, as well as methods for modulating tissue growth, for imaging tissues and organs, and for treating patients. Isolated nucleic acid and amino acid sequences for Ret ligands are disclosed. Ret ligands encoded by the isolated nucleic acid sequences of the invention have a hydrophobic N-terminal signal sequence, a hydrophobic C-terminal sequence and a phosphatidylinositol glycan linkage motif. Vectors and host cells that include Ret ligands encoded by the isolated nucleic acid sequences of the invention are also disclosed.Type: GrantFiled: November 6, 1998Date of Patent: January 13, 2004Assignee: Biogen, Inc.Inventors: Michele Sanicola-Nadel, Catherine Hession, Richard L. Cate, Dane S. Worley
-
Patent number: 6664385Abstract: Proteins which are upregulated in injured or regenerating tissues, as well as the DNA encoding these proteins, are disclosed, as well as therapeutic compositions and methods of treatment encompassing these compounds.Type: GrantFiled: November 23, 1998Date of Patent: December 16, 2003Assignee: Biogen, Inc.Inventors: Michele Sanicola-Nadel, Joseph V. Bonventre, Catherine Hession, Takaharu Ichimura, Henry Wei, Richard L. Cate
-
Publication number: 20030124704Abstract: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.Type: ApplicationFiled: October 6, 2001Publication date: July 3, 2003Inventors: Stephen M. Strittmatter, Richard L. Cate, Dinah W. Y. Sah
-
Publication number: 20030073100Abstract: Disclosed are methods of identifying renalgenerative agensts using differential gene expression. Also disclosed are methods of treating renal disorders.Type: ApplicationFiled: April 1, 2002Publication date: April 17, 2003Inventors: John A. Peyman, Eero Lehtonen, Oswald R. Crasta, Richard L. Cate
-
Publication number: 20020142284Abstract: Disclosed are methods of identifying toxic agents, e.g., renal toxic agents, using differential gene expression. Also disclosed are novel nucleic acid sequences whose expression is differentially regulated by renal injury agents.Type: ApplicationFiled: July 13, 2001Publication date: October 3, 2002Inventors: Debasish Raha, Cyndi D. Green, Richard L. Cate
-
Patent number: 6127332Abstract: A IFN-.beta. mutein in which phe (F), tyr (Y), trp (W) or his (H) is substituted for val (V) at position 101, when numbered in accordance with wild type IFN-.beta., DNA sequences encoding these IFN-.beta. muteins, recombinant DNA molecules containing those DNA sequences operatively linked to expression control sequences and capable of inducing expression of an IFN-.beta. mutein, hosts transformed with those recombinant DNA molecules, pharmaceutical compositions containing IFN-.beta. muteins and methods for treating viral infections, cancer or tumors, undesired cell proliferation, or for immunomodulation.Type: GrantFiled: August 18, 1997Date of Patent: October 3, 2000Assignee: Biogen, Inc.Inventors: Susan E. Goelz, Richard L. Cate, E. Pingchang Chow, R. Blake Pepinsky
-
Patent number: 5545723Abstract: A IFN-.beta. mutein in which phe (F), tyr (Y), trp (W) or his (H) is substituted for val (V) at position 101, when numbered in accordance with wild type IFN-.beta., DNA sequences encoding these IFN-.beta. muteins, recombinant DNA molecules containing those DNA sequences operatively linked to expression control sequences and capable of inducing expression of an IFN-.beta. mutein, hosts transformed with those recombinant DNA molecules, pharmaceutical compositions containing IFN-.beta. muteins and methods of using those compositions to treat viral infections, cancer or tumors or for immunomodulation.Type: GrantFiled: March 15, 1994Date of Patent: August 13, 1996Assignee: Biogen Inc.Inventors: Susan E. Goelz, Richard L. Cate, E. Pingchang Chow, R. Blake Pepinsky
-
Patent number: 5427780Abstract: Mullerian Inhibiting Substance (MIS)-like polypeptide are described. The MIS-like polypeptides are useful in the treatment of ovarian cancer and other susceptible cancers.Type: GrantFiled: October 5, 1992Date of Patent: June 27, 1995Assignees: Biogen, Inc., The General Hospital CorporationInventors: Richard L. Cate, Patricia K. Donahoe
-
Patent number: 5359033Abstract: This invention relates to cleaved dimers of Mullerian inhibiting substance-like polypeptides. More particularly, this invention relates to such dimers, methods of producing them and methods of using them in the treatment of cancer and tumors, especially those of the female genital tract. The dimers of this invention are also useful in compositions and methods for contraception.Type: GrantFiled: June 23, 1993Date of Patent: October 25, 1994Assignee: Biogen, Inc.Inventors: Richard L. Cate, R. Blake Pepinsky
-
Patent number: 5109124Abstract: A polynucleotide probe with a label bearing a plurality of signalling moieties. The label is attached to the probe by the reaction of an amino and sulfhydryl reactive hetero bifunctional reagent with the probe and label, the reaction resulting in the oxidation of a sulfhydryl group of the label. The label may be attached to the 5' terminus of the probe, or to modified bases of the probe. Probes constructed according to the invention are useful in detecting target sequences in genomic DNA.Type: GrantFiled: February 2, 1989Date of Patent: April 28, 1992Assignee: Biogen, Inc.Inventors: Kuzhalmannam L. Ramachandran, Richard L. Cate
-
Patent number: 5047336Abstract: DNA sequences coding for at least one MIS-like polypeptide, recombinant DNA molecules comprising such sequences, hosts comprising such sequences and processes for producing such polypeptides in hosts transformed with those DNA sequences. The MIS-like polypeptides are useful in the treatment of ovarian cancer and other susceptible cancers.Type: GrantFiled: October 30, 1985Date of Patent: September 10, 1991Assignees: Biogen, Inc., The General Hospital CorporationInventors: Richard L. Cate, Patricia K. Donahoe